RG
TEVA icon

Renaissance Group’s Teva Pharmaceuticals TEVA Stock Holding History

Renaissance Group’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.8M Sell
259,731
-23,890
-8% -$796K 0.36% 80
2026
Q1 		$8.54M Sell
283,621
-8,294
-3% -$267K 0.36% 83
2025
Q4 		$9.11M Sell
291,915
-22,655
-7% -$558K 0.37% 68
2025
Q3 		$6.35M Sell
314,570
-2,280
-0.7% -$40K 0.24% 116
2025
Q2 		$5.31M Buy
316,850
+19,313
+6% +$312K 0.21% 119
2025
Q1 		$4.57M Sell
297,537
-52,204
-15% -$933K 0.2% 105
2024
Q4 		$7.74M Sell
349,741
-20,167
-5% -$367K 0.32% 67
2024
Q3 		$6.67M Sell
369,908
-8,229
-2% -$144K 0.27% 75
2024
Q2 		$6.14M Buy
+378,137
New +$5.82M 0.24% 90
2016
Q4 		– Sell
-236,526
Closed -$10.9M – 299
2016
Q3 		$10.9M Buy
236,526
+10,659
+5% +$556K 0.44% 109
2016
Q2 		$11.3M Sell
225,867
-2,429
-1% -$129K 0.48% 101
2016
Q1 		$12.2M Sell
228,296
-3,335
-1% -$196K 0.49% 102
2015
Q4 		$15.2M Sell
231,631
-52
-0% -$3.21K 0.6% 63
2015
Q3 		$13.1M Buy
231,683
+3,244
+1% +$210K 0.52% 81
2015
Q2 		$13.5M Buy
228,439
+10,359
+5% +$639K 0.52% 93
2015
Q1 		$13.6M Buy
+218,080
New +$12.7M 0.51% 84

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Renaissance Group's TEVA Position: Q2 2026 in Review

Renaissance Group reduced its Teva Pharmaceuticals (TEVA) stake by 8.4% in Q2 2026, selling an estimated $796K and leaving 259,731 shares worth $8.8M. The position accounts for 0.36% of the portfolio, ranked #80.

Renaissance Group first reported a position in TEVA in Q1 2015 and has held it in 16 quarters since. The position peaked at $15.2M in Q4 2015. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Renaissance Group held 259,731 shares of Teva Pharmaceuticals worth $8.8M as of Q2 2026.
  • Renaissance Group sold 23,890 Teva Pharmaceuticals shares in Q2 2026, an estimated $796K.
  • Teva Pharmaceuticals made up 0.36% of Renaissance Group's portfolio in Q2 2026, its #80 holding.
  • Renaissance Group first reported a position in Teva Pharmaceuticals in Q1 2015 and has held it in 16 quarters since.
  • Renaissance Group's Teva Pharmaceuticals position peaked at $15.2M in Q4 2015.
  • 672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Renaissance Group's 13F filing for Q2 2026, filed 13 Aug 2026.